Medifast (NYSE:MED) Stock Crosses Above 200-Day Moving Average – Time to Sell?

14 Jun 2026, 09:37 by Jessica Moore · The Cerbat Gem

Medifast Inc (NYSE:MED – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $11.21 and traded as high as $12.04. Medifast shares last traded at $11.8630, with a volume of 111,571 shares traded.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Stephens reduced their target price on Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 19th. Wall Street Zen raised Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings cut Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Medifast has a consensus rating of “Reduce” and a consensus price target of $12.00.

Get Our Latest Analysis on MED

Medifast Price Performance

The stock has a market capitalization of $131.92 million, a PE ratio of -6.48 and a beta of 0.62. The firm’s 50 day simple moving average is $11.72 and its 200 day simple moving average is $11.21.

Medifast (NYSE:MED – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.36. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. The firm had revenue of $76.04 million during the quarter, compared to analyst estimates of $69.20 million. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. Analysts expect that Medifast Inc will post -1.97 earnings per share for the current fiscal year.

Insider Activity

In other Medifast news, CEO Daniel R. Chard purchased 17,678 shares of the business’s stock in a transaction on Friday, March 20th. The stock was acquired at an average cost of $10.11 per share, for a total transaction of $178,724.58. Following the completion of the transaction, the chief executive officer directly owned 17,678 shares in the company, valued at approximately $178,724.58. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Scott Schlackman acquired 2,500 shares of Medifast stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $12.53 per share, for a total transaction of $31,325.00. Following the completion of the purchase, the director directly owned 30,549 shares of the company’s stock, valued at approximately $382,778.97. The trade was a 8.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 22,678 shares of company stock valued at $241,675. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Medifast

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Empowered Funds LLC lifted its position in Medifast by 59.9% in the first quarter. Empowered Funds LLC now owns 71,584 shares of the specialty retailer’s stock valued at $729,000 after purchasing an additional 26,811 shares during the last quarter. Quantinno Capital Management LP grew its holdings in shares of Medifast by 15.1% in the first quarter. Quantinno Capital Management LP now owns 56,153 shares of the specialty retailer’s stock worth $572,000 after purchasing an additional 7,346 shares during the last quarter. State of Wyoming increased its stake in shares of Medifast by 19.8% in the first quarter. State of Wyoming now owns 6,646 shares of the specialty retailer’s stock worth $68,000 after buying an additional 1,097 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Medifast by 10.9% in the first quarter. Dimensional Fund Advisors LP now owns 361,762 shares of the specialty retailer’s stock worth $3,686,000 after buying an additional 35,522 shares during the period. Finally, Corient Private Wealth LLC bought a new stake in Medifast during the 4th quarter valued at $139,000. 95.51% of the stock is currently owned by institutional investors.

Medifast Company Profile

(Get Free Report)

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.